ATE537158T1 - M-stage-kinesin-inhibitor - Google Patents

M-stage-kinesin-inhibitor

Info

Publication number
ATE537158T1
ATE537158T1 AT04728012T AT04728012T ATE537158T1 AT E537158 T1 ATE537158 T1 AT E537158T1 AT 04728012 T AT04728012 T AT 04728012T AT 04728012 T AT04728012 T AT 04728012T AT E537158 T1 ATE537158 T1 AT E537158T1
Authority
AT
Austria
Prior art keywords
lower alkyl
substituted
atom
unsubstituted lower
kinesin inhibitor
Prior art date
Application number
AT04728012T
Other languages
English (en)
Inventor
Chikara Murakata
Yoshinori Yamashita
Ryuichiro Nakai
Kazuhito Akasaka
Yoji Ino
Kazuhiko Kato
Yushi Kitamura
Original Assignee
Kyowa Hakko Kirin Co Ltd
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Fujifilm Corp filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE537158T1 publication Critical patent/ATE537158T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04728012T 2003-04-18 2004-04-16 M-stage-kinesin-inhibitor ATE537158T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003114071 2003-04-18
JP2003164727 2003-06-10
PCT/JP2004/005489 WO2004092147A1 (ja) 2003-04-18 2004-04-16 Ｍ期キネシン阻害剤

Publications (1)

Publication Number Publication Date
ATE537158T1 true ATE537158T1 (de) 2011-12-15

Family

ID=33302241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04728012T ATE537158T1 (de) 2003-04-18 2004-04-16 M-stage-kinesin-inhibitor

Country Status (10)

Country Link
US (3) US7851635B2 (de)
EP (2) EP2327702B1 (de)
JP (1) JP4676881B2 (de)
KR (1) KR101096948B1 (de)
CN (2) CN101787000B (de)
AT (1) ATE537158T1 (de)
AU (1) AU2004230799B2 (de)
CA (1) CA2522594C (de)
ES (2) ES2377498T3 (de)
WO (1) WO2004092147A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480527T1 (de) 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
KR101096948B1 (ko) * 2003-04-18 2011-12-20 후지필름 홀딩스 가부시끼가이샤 Ｍ기 키네신 저해제
CA2528433A1 (en) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
JPWO2005035512A1 (ja) * 2003-10-10 2006-12-21 協和醗酵工業株式会社 チアジアゾリン誘導体
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193877A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
CN101193878A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 实体肿瘤治疗剂
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
US8324257B2 (en) * 2006-10-03 2012-12-04 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
JP4875205B2 (ja) * 2007-07-12 2012-02-15 イーライ リリー アンド カンパニー チアジアゾール誘導体の安定な製剤
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338449A (en) * 1981-06-15 1982-07-06 Eli Lilly And Company Herbicidal thiadiazolines
US4346225A (en) 1981-06-15 1982-08-24 Eli Lilly And Company Herbicidal 2-methylamino thiadiazolines
US4699913A (en) * 1985-06-28 1987-10-13 Ciba-Geigy Corporation Substituted 4,5-dihydro-1,3,4-thiadiazoles useful as insecticides
ATE72431T1 (de) 1985-08-31 1992-02-15 Fisons Plc 5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren.
DD243930A1 (de) 1985-12-04 1987-03-18 Akad Wissenschaften Ddr Verfahren zur herstellung von neuen 5,5-disubstituierten 4-carbamoyl-4,5-dihydro-1,3,4-thiadiazol-2-yl-harnstoffen
AU4288293A (en) 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
US5643911A (en) * 1994-05-19 1997-07-01 Mitsubishi Chemical Corporation Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
JP2798005B2 (ja) 1994-05-19 1998-09-17 三菱化学株式会社 平滑筋細胞増殖に起因する疾患の治療・予防剤
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
US6235762B1 (en) 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
JP2002534515A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー １−複素環置換されたジアリールアミン
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
JP2000229959A (ja) 1999-02-04 2000-08-22 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP1226129B1 (de) * 1999-10-27 2006-05-24 Cytokinetics, Inc. Chinazolinone benutzende verfahren und zusammenstellungen
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
WO2001056994A1 (en) 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
EP1360180A1 (de) 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazinkinesininhibitoren
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002078639A2 (en) * 2001-03-29 2002-10-10 Bristol-Myers Squibb Company A method of treating proliferative diseases using eg5 inhibitors
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE480527T1 (de) 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
EP1492487B1 (de) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotische kinesin-hemmer
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1517904A4 (de) * 2002-05-23 2007-02-21 Merck & Co Inc Inhibitoren von mitotischem kinesin
KR101096948B1 (ko) 2003-04-18 2011-12-20 후지필름 홀딩스 가부시끼가이샤 Ｍ기 키네신 저해제
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
CA2528433A1 (en) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
JPWO2005035512A1 (ja) 2003-10-10 2006-12-21 協和醗酵工業株式会社 チアジアゾリン誘導体
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193877A (zh) 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
CN101193878A (zh) 2005-03-22 2008-06-04 协和发酵工业株式会社 实体肿瘤治疗剂
WO2006137490A1 (ja) 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤

Also Published As

Publication number Publication date
AU2004230799B2 (en) 2010-03-18
JP4676881B2 (ja) 2011-04-27
AU2004230799A1 (en) 2004-10-28
EP1616866A4 (de) 2008-09-24
US7851635B2 (en) 2010-12-14
CA2522594C (en) 2012-01-24
EP1616866A1 (de) 2006-01-18
ES2394850T3 (es) 2013-02-06
CN1774428A (zh) 2006-05-17
KR20060008903A (ko) 2006-01-27
CN101787000B (zh) 2011-08-03
HK1158637A1 (en) 2012-07-20
EP2327702A1 (de) 2011-06-01
US20110004000A1 (en) 2011-01-06
CN1774428B (zh) 2010-06-16
WO2004092147A1 (ja) 2004-10-28
JPWO2004092147A1 (ja) 2006-07-06
EP2327702B1 (de) 2012-08-29
US20070155804A1 (en) 2007-07-05
US8318782B2 (en) 2012-11-27
CA2522594A1 (en) 2004-10-28
US20110275827A1 (en) 2011-11-10
CN101787000A (zh) 2010-07-28
KR101096948B1 (ko) 2011-12-20
EP1616866B1 (de) 2011-12-14
ES2377498T3 (es) 2012-03-28

Similar Documents

Publication Publication Date Title
EP1616866A4 (de) M-stage-kinesin-inhibitor
CY1112899T1 (el) Παραγωγα θειαδιαζολινης για τη θεραπεια του καρκινου
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
DE60024651D1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
EP1671957A4 (de) Thiadiazolinderivate
DE60223904D1 (de) Benzylaminanalogen
MX2007000240A (es) Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo.
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
NO20070421L (no) Radiosensitiviserende middel
DE69928749D1 (de) Lp(a)-MINDERNDE MITTEL UND INHIBITOREN DER APOPROTEIN (a) PRODUKTION
ATE284884T1 (de) Triazolderivate mit amidbindungen
ATE538118T1 (de) Pyrimidinylisoxazolderivat
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
EP1589023A4 (de) Oligosaccharidderivat
ATE481390T1 (de) Pyrazolverbindung
EP1557407A4 (de) Neue alpha-ketoamidderivate und deren verwendung
WO2003082837A1 (en) Hydroxymorpholinone derivative and medicinal use thereof